Takeda Pharmaceuticals
-
Hatfield-based Code Biotherapeutics Enters Collaboration Deal with Takeda Potentially Worth $2B
Hatfield-based Code Biotherapeutics has entered into a collaboration and option deal with Takeda with a potential value of $2 billion,…
-
King of Prussia’s CSL Behring Joins Forces to Develop Potential COVID-19 Therapy
King of Prussia-based CSL Behring has joined forces with several other biopharmaceutical companies to develop a potential plasma-derived therapy to…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
